WHO Sounds Concern Over Acute Lack of Weight-Loss Medications
Under one in 10 patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the World Health Organization as it releases its first guidance on the medications.
Considering over a billion individuals worldwide currently classified as obese, it is urging more widespread and fairer access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can aid individuals in losing significant body mass, says the agency.
Skinny Jab Shortage
Despite the present most optimistic case, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of the global need, according to the WHO.
The advice calls on countries and companies to increase availability, through approaches including patent sharing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is set to lapse in several nations in 2026.
The Way Weight-Loss Injections Work
These medications mimick a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so people reduce food intake.
Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs.
Research suggests patients may put most of the weight back on a year later of discontinuing the medication, as their typical hunger return.
To be above a healthy weight elevates your likelihood for developing medical conditions, such as diabetes, heart disease, stroke, and some malignancies.
Excess weight affects people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
